SCHEMBL25366146

SCHEMBL25366146

CC(C)N1CCN(c2ccc(-c3ccc4nc(-c5ccc(S(C)(=O)=O)cc5)n(C)c4n3)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 1/20 0.47
▸ ALK Q9UM73 4/20 0.43
▸ PTGS2 P35354 5/20 0.40
▸ SYK P43405 1/20 0.40
▸ JAK2 O60674 2/20 0.39
▸ JAK3 P52333 2/20 0.39
▸ PTK2 Q05397 2/20 0.39
▸ JAK1 P23458 1/20 0.39
▸ MAOA P21397 1/20 0.39
▸ MAOB P27338 1/20 0.39
▸ GRM2 Q14416 1/20 0.39
▸ TNF P01375 1/20 0.39
▸ AKR1C3 P42330 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ XBP1 P17861 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ KLF5 Q13887 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30557377 1.00 HRH3 (0.47) HRH3ALKPTGS2SYKJAK2
SCHEMBL25368100 0.90 HRH3 (0.37) HRH3ALKPTGS2JAK2JAK3
SCHEMBL30557460 0.90 HRH3 (0.37) HRH3ALKPTGS2JAK2JAK3
SCHEMBL30557586 0.87 PTGS2 (0.40) HRH3PTGS2MAOAMAOBGRM2
SCHEMBL25362939 0.87 PTGS2 (0.40) HRH3PTGS2MAOAMAOBGRM2
SCHEMBL25365448 0.87 HRH3 (0.43) HRH3ALKPTGS2SYKJAK2
SCHEMBL30557349 0.84 HRH3 (0.43) HRH3ALKPTGS2SYKJAK2
SCHEMBL25365599 0.84 HRH3 (0.43) HRH3ALKPTGS2SYKJAK2
SCHEMBL25364691 0.82 CYP2D6 (0.40) PTGS2JAK2JAK3PTK2JAK1
SCHEMBL30557474 0.82 CYP2D6 (0.40) PTGS2JAK2JAK3PTK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250177363-A1 SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 BRISTOL-MYERS SQUIBB COMPANY (US) 2025-06-05 — — US disclosed
WO-2023159154-A1 SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250177363-A1 SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 TLR9, TLR3, TLR1 HRH3 180/4885ALK 334/4885PTGS2 666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback